Dr. Reddy’s Q3 & 9M FY21 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Dr. Reddys Labs (RDY) Reports Q3 EPS of $0.02
January 29, 2021 5:49 AM ESTDr. Reddys Labs (NYSE: RDY) reported Q3 EPS of $0.02, versus ($0.47) reported last year. Revenue for the quarter came in at $675 million, versus $600 million reported last year.
Commenting on the results, Co-chairman & MD, G V Prasad said, We continued with our growth momentum while... More
